Metastatic melanoma with heterologous bone after neoadjuvant immunotherapy: diagnostic insights.

Abstract excerpt

We report a BRAF V600E-mutated cutaneous melanoma (pT3b) with nodal metastases treated with neoadjuvant anti-PD-1 therapy. Axillary lymph node dissection demonstrated residual viable melanoma intimately associated with extensive heterologous lamellar bone formation within the post-treatment tumor bed. Histologic assessment supported a melanoma-related heterologous component rather than a purely reactive stromal...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immune Checkpoint Inhibitors
• Share to Immunotherapy